Enzene Biosciences has appointed Norm Stoffregen as the Site Head and the Head of Biologics Manufacturing at its new manufacturing facility in Hopewell, New Jersey.
Once the site is fully commissioned, he will lead ongoing operations.
The company currently intends to transfer in the manufacturing projects of existing customers, as well as adding further bioreactor capacity at the site.
Before joining Enzene, Stoffregen was the VP-site head at PTC Therapeutics, and has worked in the bioprocessing industry for more than 20 years.
CEO of Enzene Biosciences, Himanshu Gadgil, commented: “I am delighted to welcome Norman to Enzene,”
"His knowledge of the facility, our colleagues, customers and suppliers will be invaluable as we develop our customer base and expand operations, further building our reputation as a world class biologics innovator dedicated to lowering the cost of biologics production, and continually improving manufacturing techniques.”